- Home
- LEGH vs CMPX Comparison
LEGH vs CMPX Comparison
Compare LEGH & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- CMPX
- Stock Information
- Founded
- LEGH 2005
- CMPX 2014
- Country
- LEGH United States
- CMPX United States
- Employees
- LEGH N/A
- CMPX N/A
- Industry
- LEGH Homebuilding
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- CMPX Health Care
- Exchange
- LEGH Nasdaq
- CMPX Nasdaq
- Market Cap
- LEGH 646.4M
- CMPX 576.5M
- IPO Year
- LEGH 2018
- CMPX N/A
- Fundamental
- Price
- LEGH $24.90
- CMPX $3.70
- Analyst Decision
- LEGH Strong Buy
- CMPX Strong Buy
- Analyst Count
- LEGH 1
- CMPX 7
- Target Price
- LEGH $29.00
- CMPX $14.71
- AVG Volume (30 Days)
- LEGH 68.6K
- CMPX 1.6M
- Earning Date
- LEGH 11-11-2025
- CMPX 11-11-2025
- Dividend Yield
- LEGH N/A
- CMPX N/A
- EPS Growth
- LEGH 2.38
- CMPX N/A
- EPS
- LEGH 2.23
- CMPX N/A
- Revenue
- LEGH $184,284,000.00
- CMPX N/A
- Revenue This Year
- LEGH $1.51
- CMPX N/A
- Revenue Next Year
- LEGH $7.92
- CMPX N/A
- P/E Ratio
- LEGH $11.25
- CMPX N/A
- Revenue Growth
- LEGH 8.79
- CMPX N/A
- 52 Week Low
- LEGH $21.58
- CMPX $1.27
- 52 Week High
- LEGH $29.45
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- LEGH 30.29
- CMPX 57.44
- Support Level
- LEGH $26.90
- CMPX $3.31
- Resistance Level
- LEGH $27.59
- CMPX $3.83
- Average True Range (ATR)
- LEGH 0.88
- CMPX 0.23
- MACD
- LEGH -0.26
- CMPX -0.02
- Stochastic Oscillator
- LEGH 4.43
- CMPX 75.95
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.